Adjuvant chemotherapy appeared associated with a significant survival benefit among patients with pancreatic ductal adenocarcinoma who underwent multiagent neoadjuvant chemotherapy and resection, according to study results.Investigators observed the survival benefit regardless patients lymph node status or resection margins.